[Surgical management of macular edema].
Yamamoto
Teiko
T
Department of Ocular Cellular Engineering, Yamagata University Hospital.
D002199:Capillary Permeability; D003131:Combined Modality Therapy; D003930:Diabetic Retinopathy / Q000209:etiology / Q000601:surgery*; D006801:Humans; D015850:Interleukin-6 / Q000302:isolation & purification; D008269:Macular Edema / Q000209:etiology / Q000601:surgery*; D010100:Oxygen / Q000378:metabolism; D010313:Partial Pressure; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000009:adverse effects; D014409:Tumor Necrosis Factor-alpha / Q000302:isolation & purification; D042461:Vascular Endothelial Growth Factor A / Q000302:isolation & purification; D014821:Vitrectomy / Q000379:methods
D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D042461:Vascular Endothelial Growth Factor A; D014222:Triamcinolone Acetonide; D010100:Oxygen